emedicine.com

Legionnaires Disease: Background, Pathophysiology, Etiology

  • ️Invalid Date

Overview

Background

Legionnaires disease (LD) is the pneumonia caused by Legionella pneumophila. Legionnaires disease also refers to a more benign, self-limited, acute febrile illness known as Pontiac fever, which has been linked serologically to L pneumophila, although it presents without pneumonia. Pontiac fever usually is self-limiting and typically does not require antibiotics administration. [1, 2, 3, 4]  

L pneumophila is an important cause of nosocomial and community-acquired pneumonia (CAP) and must be considered a possible causative pathogen in any patient who presents with atypical pneumonia. Empiric antibiotic coverage for CAP usually includes classes of antibiotics that have Legionella coverage such as fluroquinolones, macrolides and tetracyclines.

The Legionella bacterium first was identified in the summer of 1976 during the 58th annual convention of the American Legion, which was held at the Bellevue-Stratford Hotel in Philadelphia. Infection was presumed to be spread by contamination of the water in the hotel's air conditioning system. The presentation ranged from mild flulike symptoms to multisystem organ failure. Of the 182 people infected, 29 died.

Although Legionella was not identified until 1976, L pneumophila subsequently was found in a clinical specimen dating to 1943 and, according to retrospective analysis, may have been responsible for pre-1976 pneumonia epidemics in Philadelphia; Washington, DC; and Minnesota.

Legionnaires disease is the term that collectively describes infections caused by members of the Legionellaceae family.

Bacterial characteristics

The Legionella bacterium is a small, aerobic, waterborne, gram-negative, unencapsulated bacillus that is nonmotile, catalase-positive, and weakly oxidase-positive. It is a fastidious organism and does not grow anaerobically or on standard media. Buffered charcoal yeast extract (CYE) agar is the primary medium used for isolation of the bacterium. [1, 2, 3, 4]  

The Legionellaceae family consists of more than 42 species, constituting 64 serogroups. L pneumophila is the most common species, causing up to 90% of the cases of Legionellosis, followed by L micdadei (otherwise known as the Pittsburgh pneumonia agent), L bozemanii, L dumoffii, and L longbeachae. Fifteen serogroups of L pneumophila have been identified, with serogroups 1, 4, and 6 being the primary causes of human disease. Serogroup 1 is thought to be responsible for 80% of the reported cases of legionellosis caused by L pneumophila. [5]

Patient education

For patient education information, see Bronchoscopy.

eMedicine Logo

Pathophysiology

Legionella species are obligate or facultative intracellular parasites. Water is the major environmental reservoir for Legionella; the bacteria can infect and replicate within protozoa such as Acanthamoeba and Hartmannella, which are free-living amoebae found in natural and manufactured water systems. (Legionellae can resist low levels of chlorine used in water distribution systems.) [4]

Within the amebic cells, Legionella species can avoid the endosomal-lysosomal pathway and can replicate within the phagosome. Surviving and growing in amebic cells allows Legionella to persist in nature. 

This electron micrograph depicts an amoeba, Hartma

This electron micrograph depicts an amoeba, Hartmannella vermiformis (orange), as it entraps a Legionella pneumophila bacterium (green) with an extended pseudopod. After it is ingested, the bacterium can survive as a symbiont within what then becomes its protozoan host. The amoeba then becomes a so-called "Trojan horse," since, by harboring the pathogenic bacterium, the amoeba can afford it protection. In fact, in times of adverse environmental conditions, the amoeba can metamorphose into a cystic stage, enabling it, and its symbiotic resident, to withstand the environmental stress. Image courtesy of the Centers for Disease Control and Prevention and Dr. Barry S Fields.

Legionella species infect human macrophages and monocytes; intracellular replication of the bacterium is observed within these cells in the alveoli. The intracellular infections of protozoa and macrophages have many similarities. [4]

Activated T cells produce lymphokines that stimulate increased antimicrobial activity of macrophages. This cell-mediated activation is key to halting the intracellular growth oflegionellae. The significant role of cellular immunity explains why legionellae are observed more frequently in immunocompromised patients. Humoral immunity is thought to play a secondary role in the host response to Legionella infection.

eMedicine Logo

Etiology

Legionella transmission is thought to occur via inhalation of aerosolized mist from water sources, such as the following, that have been contaminated with the bacterium [4, 6, 7, 8, 9] :

  • Cooling systems

  • Showers

  • Decorative fountains

  • Humidifiers

  • Respiratory therapy equipment

  • Whirlpool spas

  • Ice machines

  • Potting soil (L longbeachae spp) 

  • Compost (L longbeachae spp) 

  • Roadside puddles

  • Tubs used for water births [10]

Legionnaires disease (LD) may be travel associated from exposure in aircraft or hotel facilities. Person-to-person transmission, however, has not been documented.

The highest incidence of LD occurs during late spring and early fall, when air-conditioning systems are used more frequently. [11, 12] Nosocomial acquisition likely occurs via aspiration, respiratory therapy equipment, [8] or contaminated water. In addition, transmission has been linked to the use of humidifiers, nebulizers, and items that were rinsed with contaminated tap water.

The following features increase the likelihood of colonization and amplification of legionellae in human-made water environments:

  • Temperature of 25-42°C

  • Stagnation

  • Scale and sediment

  • Presence of certain free-living aquatic amoebae capable of supporting intracellular growth of legionellae

Risk factors

The risk for infection increases with the type and intensity of the exposure, as well as the health status of the exposed individual. Numerous factors increase the risk of acquiring Legionella infections, including the following:

  • Advanced age

  • Smoking

  • Chronic heart or lung disease

  • Immunocompromised hosts with impaired cell-mediated immunity (eg, acquired immunodeficiency syndrome [AIDS]) or immunosuppressive medication use (especially corticosteroids)

  • Diabetes

  • Hematologic malignancies

  • End-stage renal disease

  • Alcohol abuse

eMedicine Logo

Epidemiology

Occurrence in the United States

Legionnaires disease (LD) has a reported incidence of 8000-18,000 cases per year. In certain geographic areas, community-acquired LD is more common. Although LD is reportable in all 50 states, it is estimated that only 5-10% of cases are reported. Although most cases of the disease are sporadic, 10-20% are linked to outbreaks. Legionnaires disease is more common in the summer, especially in August, and is slightly more prevalent in the northern United Sates. [1, 2, 4]

Prevalence reports for Legionella have increased with time, likely due to the availability of more effective testing modalities. However, it also is possible that Legionella infections are increasing in frequency for environmental, population-based, or behavioral reasons.

Legionnaires disease is among the top 3-4 microbial causes of CAP, constituting approximately 1-9% of patients with CAP who require hospitalization. Legionnaires disease is an even more common cause of severe pneumonia in patients who require admission to an intensive care unit (ICU), ranking second, after pneumococcal pneumonia, in such cases. In addition, it is recognized as the most common cause of atypical pneumonia in hospitalized patients.

Legionnaires disease cases acquired in the hospital usually occur as outbreaks and most often result from the presence of Legionella in water sources and on surfaces (eg, pipes, rubber, plastics). The organism also is found in water sediment, which may explain its ability to persist despite flushing of hospital water systems. [13, 14]

Barsky et al compared epidemiological patterns of LD cases reported to the US Centers for Disease Control and Prevention before and during a rise in cases. The average age-standardized incidence was 0.48 cases per 100,000 population from 1992 to 2002, significantly increasing to 2.71 cases per 100,000 in 2018. Reported cases increased across all demographic groups, and the rise was more substantial in groups with initially higher incidence rates. White individuals accounted for the largest number of cases overall, but Black or African-American individuals had the highest incidence rate. Incidence and increases were most notable in the East North Central, Middle Atlantic, and New England regions. Seasonality, particularly in the Northeast and Midwest, became more pronounced from 2003 to 2018. The rising incidence of Legionnaires' disease was prominently linked to increasing racial disparities, geographical concentration, and seasonality. [15]

International occurrence

Legionnaires disease is thought to occur worldwide and to be the cause of 2-15% of all CAP cases that require hospitalization. Outbreaks have been recognized throughout North America, Africa, Australia, Europe, and South America.

Sex- and age-related demographics

Men have a greater risk of acquiring L pneumophila infection. Older age is another risk factor; the weighted mean age for patients with LD is 52.7 years, with increasing incidence until age 79 years. Mortality rates also are higher in older patients. The incidence of LD in persons younger than 35 years is less than 0.1 cases per 100,000 people.

eMedicine Logo

Prognosis

Recovery is variable in Legionnaires disease (LD); some patients experience rapid improvement, whereas others have a much more protracted course despite treatment. The mortality rate approaches 50% with nosocomial infections. [4]

Progressive respiratory failure is the most common cause of death in patients with Legionella pneumonia. However, the mortality rate depends on the comorbid conditions of the patient, as well as on the choice and timeliness of antibiotics administration. The site of acquisition (eg, nosocomial, community-acquired) also may affect the outcome.

eMedicine Logo

Complications

Potential complications include the following [4] :

  • Decreased pulmonary function

  • Fulminant respiratory failure

  • Dehydration, septic shock

  • Respiratory insufficiency, hypoxic respiratory failure

  • Endocarditis

  • Neurologic symptoms: Including lethargy, headache, altered mental status, and nonfocal neurologic examination findings

  • Gastrointestinal symptoms: Diarrhea, vomiting

  • Multiple organ failure

  • Coma

  • Bacteremia or abscess formation (in the lungs or at extrapulmonary sites) in immunocompromised patients

  • Death: In 10% of treated nonimmunocompromised patients and in as many as 80% of untreated immunocompromised patients

A study by van Loenhout et al that included 190 patients with LD found that a year after the disease’s onset, many patients were still suffering from 1 or more adverse health effects, particularly fatigue and reduced general quality of life. [16]

eMedicine Logo

  1. [Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. October 10, 2019. 44 Suppl 2:S27-72. [QxMD MEDLINE Link]. [Full Text].

  2. [Guideline] CDC. Clinical Guidance for Legionella Infections. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/legionella/hcp/clinical-guidance/index.html. January 29, 2024; Accessed: September 9, 2024.

  3. [Guideline] Viasus D, Gaia V, Manzur-Barbur C, Carratalà J. Legionnaires' Disease: Update on Diagnosis and Treatment. Infect Dis Ther. 2022 Jun. 11 (3):973-986. [QxMD MEDLINE Link]. [Full Text].

  4. WHO. Legionellosis. World Health Organization. Available at https://www.who.int/news-room/fact-sheets/detail/legionellosis. September 6, 2022; Accessed: September 9, 2024.

  5. Kozak-Muiznieks NA, Lucas CE, Brown E, Pondo T, Taylor TH Jr, Frace M, et al. Prevalence of sequence types among clinical and environmental isolates of Legionella pneumophila serogroup 1 in the United States from 1982 to 2012. J Clin Microbiol. 2014 Jan. 52(1):201-11. [QxMD MEDLINE Link]. [Full Text].

  6. WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. World Health Organization. Available at https://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air. April 18, 2024; Accessed: April 25, 2024.

  7. Nguyen TM, Ilef D, Jarraud S, Rouil L, Campese C, Che D. A community-wide outbreak of legionnaires disease linked to industrial cooling towers--how far can contaminated aerosols spread?. J Infect Dis. 2006 Jan 1. 193(1):102-11. [QxMD MEDLINE Link].

  8. Woo AH, Goetz A, Yu VL. Transmission of Legionella by respiratory equipment and aerosol generating devices. Chest. 1992 Nov. 102(5):1586-90. [QxMD MEDLINE Link].

  9. Kenagy E, Priest PC, Cameron CM, Smith D, Scott P, Cho V, et al. Risk Factors for Legionella longbeachae Legionnaires' Disease, New Zealand. Emerg Infect Dis. 2017 Jul. 23 (7):1148-1154. [QxMD MEDLINE Link].

  10. Granseth G, Bhattarai R, Sylvester T, Prasai S, Livar E. Notes from the Field: Two Cases of Legionnaires' Disease in Newborns After Water Births - Arizona, 2016. MMWR Morb Mortal Wkly Rep. 2017 Jun 9. 66 (22):590-591. [QxMD MEDLINE Link].

  11. Brandsema PS, Euser SM, Karagiannis I, DEN Boer JW, VAN DER Hoek W. Summer increase of Legionnaires' disease 2010 in The Netherlands associated with weather conditions and implications for source finding. Epidemiol Infect. 2014 Jan 24. 1-12. [QxMD MEDLINE Link].

  12. Halsby KD, Joseph CA, Lee JV, Wilkinson P. The relationship between meteorological variables and sporadic cases of Legionnaires' disease in residents of England and Wales. Epidemiol Infect. 2014 Jan 9. 1-8. [QxMD MEDLINE Link].

  13. Cristino S, Legnani PP, Leoni E. Plan for the control of Legionella infections in long-term care facilities: Role of environmental monitoring. Int J Hyg Environ Health. 2011 Sep 16. [QxMD MEDLINE Link].

  14. Lin YE, Stout JE, Yu VL. Controlling Legionella in hospital drinking water: an evidence-based review of disinfection methods. Infect Control Hosp Epidemiol. 2011 Feb. 32(2):166-73. [QxMD MEDLINE Link].

  15. Barskey AE, Derado G, Edens C. Rising Incidence of Legionnaires' Disease and Associated Epidemiologic Patterns, United States, 1992-2018. Emerg Infect Dis. 2022 Mar. 28 (3):527-538. [QxMD MEDLINE Link]. [Full Text].

  16. van Loenhout JA, van Tiel HH, van den Heuvel J, Vercoulen JH, Bor H, van der Velden K, et al. Serious long-term health consequences of Q-fever and Legionnaires' disease. J Infect. 2014 Jan 25. [QxMD MEDLINE Link].

  17. Franco-Garcia A, Varughese TA, Lee YJ, Papanicolaou G, Rosenblum MK, Hollmann TJ, et al. Diagnosis of Extrapulmonary Legionellosis in Allogeneic Hematopoietic Cell Transplant Recipients by Direct 16S Ribosomal Ribonucleic Acid Sequencing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Open Forum Infect Dis. 2017 Summer. 4 (3):ofx140. [QxMD MEDLINE Link].

  18. Qin X, Abe PM, Weissman SJ, Manning SC. Extrapulmonary Legionella micdadei infection in a previously healthy child. Pediatr Infect Dis J. 2002 Dec. 21 (12):1174-6. [QxMD MEDLINE Link].

  19. [Guideline] CDC. Clinical Features of Legionnaires' Disease and Pontiac Fever. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/legionella/hcp/clinical-signs/index.html. January 29, 2024; Accessed: September 9, 2024.

  20. Rello J, Allam C, Ruiz-Spinelli A, Jarraud S. Severe Legionnaires' disease. Ann Intensive Care. 2024 Apr 2. 14 (1):51. [QxMD MEDLINE Link]. [Full Text].

  21. CDC. What Clinicians Need to Know about Legionnaires Disease. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/legionella/downloads/fs-legionella-clinicians.pdf. Accessed: September 9, 2024.

  22. Cunha BA. Hypophosphatemia: diagnostic significance in Legionnaires' disease. Am J Med. 2006 Jul. 119(7):e5-6. [QxMD MEDLINE Link].

  23. Hunter CM, Salandy SW, Smith JC, Edens C, Hubbard B. Racial Disparities in Incidence of Legionnaires' Disease and Social Determinants of Health: A Narrative Review. Public Health Rep. 2022 Jul-Aug. 137 (4):660-671. [QxMD MEDLINE Link]. [Full Text].

  24. Kashuba AD, Ballow CH. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis. 1996 Mar. 24(3):129-39. [QxMD MEDLINE Link].

  25. Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest. 2000 Feb. 117(2):398-403. [QxMD MEDLINE Link].

  26. Bopp LH, Baltch AL, Ritz WJ, Michelsen PB, Smith RP. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages. Diagn Microbiol Infect Dis. 2011 Jan. 69 (1):86-93. [QxMD MEDLINE Link].

  27. Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L, Ramos Guevara RM, Sánchez-Nieto JM, Segovia Hernández M, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. 2005 Mar 15. 40 (6):800-6. [QxMD MEDLINE Link].

  28. [Guideline] Arizona Department of Health Services. Guidelines for water immersion and water birth. ADHS. Available at https://www.azdhs.gov/documents/licensing/special/midwives/training/guidelines-for-water-immersion-water-birth.pdf. November 2016; Accessed: June 9, 2017.

  29. Mondino S, Schmidt S, Rolando M, Escoll P, Gomez-Valero L, Buchrieser C. Legionnaires' Disease: State of the Art Knowledge of Pathogenesis Mechanisms of Legionella. Annu Rev Pathol. 2020 Jan 24. 15:439-466. [QxMD MEDLINE Link]. [Full Text].

  30. Jong B, Hallström LP. European Surveillance of Legionnaires' Disease. Curr Issues Mol Biol. 2021. 42:81-96. [QxMD MEDLINE Link]. [Full Text].

  • This electron micrograph depicts an amoeba, Hartmannella vermiformis (orange), as it entraps a Legionella pneumophila bacterium (green) with an extended pseudopod. After it is ingested, the bacterium can survive as a symbiont within what then becomes its protozoan host. The amoeba then becomes a so-called "Trojan horse," since, by harboring the pathogenic bacterium, the amoeba can afford it protection. In fact, in times of adverse environmental conditions, the amoeba can metamorphose into a cystic stage, enabling it, and its symbiotic resident, to withstand the environmental stress. Image courtesy of the Centers for Disease Control and Prevention and Dr. Barry S Fields.

Author

Chinelo N Animalu, MD, MPH, FIDSA Associate Professor, Division of Infectious Diseases, Department of Internal Medicine, University of Tennessee Health Science Center College of Medicine; Physician, Department of Infectious Disease, University of Tennessee Methodist Physicians (UTMP), Methodist University Hospital

Chinelo N Animalu, MD, MPH, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, Memphis Medical Society, Tennessee Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Frank C Smeeks, III, MD Specialty Medical Director of Emergency Medicine, Applied Medico Legal Solutions

Frank C Smeeks, III, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Association for Physician Leadership, American Medical Association, North Carolina Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

Joseph F John Jr, MD, FACP, FIDSA, FSHEA Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Eric M Kardon, MD, FACEP Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center

Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Fred A Lopez, MD Associate Professor and Vice Chair, Department of Medicine, Assistant Dean for Student Affairs, Louisiana State University School of Medicine

Fred A Lopez, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, Infectious Diseases Society of America, and Louisiana State Medical Society

Disclosure: Nothing to disclose.

Scott Savage, DO Associate Clinical Faculty, Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Lynn E Sullivan, MD Assistant Professor of Medicine, Yale University School of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jeter (Jay) Pritchard Taylor III, MD Compliance Officer, Attending Physician, Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Health Richland, University of South Carolina School of Medicine; Medical Director, Department of Emergency Medicine, Palmetto Health Baptist

Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.